HAVCR2 and neoplasm: Consequently, C1 patients might require the combination treatment discussed earlier, integrating radiotherapy with drugs blocking TIM3 and PD-1, to stimulate the tumor’s internal immune response, activate T-cells, and kill tumor cells (Kim et al., 2017).